Hormonal
Dual agonists of GLP-1 and glucagon (GCGR) or GIP receptors provide greater weight loss and broader metabolic benefits than mono-agonists, potentially addressing treatment barriers like cost and access by treating non-cardiometabolic complications.
If you have obesity, especially with related conditions like diabetes or fatty liver, newer dual-agonist medications (like tirzepatide) may offer significantly greater weight loss and health benefits than older drugs. However, access is currently limited by cost and insurance coverage. Discuss these options with your doctor, focusing on how treating multiple complications might justify the expense.
The hope is that their dual receptor activity will elicit substantial weight loss and potentially provide additional weight-independent reduction of ABCD complications... dual GCGR/GLP-1 RA may offer additional benefits, potentially addressing treatment barriers and access.
Why this rating
Based on a large cross-sectional survey of healthcare professionals (n=785) regarding their knowledge and expectations of these drugs, supported by cited clinical trial data for efficacy.
Source
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
W. Timothy Garvey et al. · Obesity Science & Practice · 2024
DOI 10.1002/osp4.756
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →